Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma Market

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.

World revenue for the ophthalmic drugs market, in terms of value, is forecast to surpass US$35 billion in 2025, with strong revenue growth through to 2035.

The global ophthalmic drugs market is experiencing robust growth, driven by several key factors. Rising incidences of eye-related conditions - such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome - are fuelling the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options.

A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.

Topical ophthalmic drugs can cause a variety of side effects, including temporary vision cloudiness, allergic reactions, visual disturbances, and stinging, burning, or itching. Less common but more severe side effects include sudden vision changes, intense headaches, tunnel vision, eye discomfort, pain behind the eyes, and signs of an eye infection, such as swelling and discharge. As a result, adverse effects, particularly those associated with topical steroidal drugs, may limit market growth.

Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals' drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss.

On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.

Key Questions Answered

• How is the ophthalmic drugs market evolving?
• What is driving and restraining the ophthalmic drugs market?
• How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each ophthalmic drugs submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
• Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

Forecasts to 2035 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.

The report also includes profiles for some of the leading companies in the Ophthalmic Drugs Market 2025 to 2035, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

• AbbVie
• Alcon
• Alimera Sciences
• Apellis Pharmaceuticals
• Bausch + Lomb
• Bayer
• Breye Therapeutics ApS
• EyeBio
• F. Hoffmann-La Roche
• Johnson & Johnson Services
• Nicox
• Novaliq
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Santen Pharmaceutical Co.
• SpliceBio
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Viatris

How will the Ophthalmic Drugs Market report help you?

• Revenue forecasts to 2035 for Ophthalmic Drugs Market Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 26 key national markets - See forecasts for the Ophthalmic Drugs Market market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 21 of the major companies involved in the Ophthalmic Drugs Market.

Key Topics Covered:

Market Driving Factors

• Rising Frequency and Occurrence of Eye-related Conditions
• Technological Advancements and Innovations
• Increasing Prevalence of Diabetes
• Presence of Strong Emerging Pipeline Drugs

Market Restraining Factors

• Lack of Health Insurance in the Developing Countries
• Lack of Awareness Regarding the Available Treatment Options
• Side Effects of Drugs
• Patent Expiry of Blockbuster Drugs
• Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
• Intensifying Competition in the Crowded Ophthalmic Drugs Market

Market Opportunities

• Rise in Investment in Research and Development
• Rise in Geriatric Population
• Emergence of Digital Health Solutions and Telemedicine
• Growing Regulatory Support for Innovation in the Ophthalmic Sector
• E-Commerce and Online Pharmacies Unlock New Market Opportunities

Ophthalmic Drugs Market Analysis by Type

• Type Segment: Market Attractiveness Index
• Ophthalmic Drugs Market Size Estimation and Forecast by Type
• Prescription Drugs
• OTC Drugs

Ophthalmic Drugs Market Analysis by Distribution Channel

• Distribution Channel Segment: Market Attractiveness Index
• Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies

Ophthalmic Drugs Market Analysis by Indication

• Indication Segment: Market Attractiveness Index
• Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• Retinal Disorders
• Infection/Inflammation/Allergy
• Dry Eye
• Glaucoma

Ophthalmic Drugs Market Analysis by Route of Administration

• Route of Administration Segment: Market Attractiveness Index
• Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• Topical
• .6 Parenteral

Ophthalmic Drugs Market Analysis by Region

For more information about this report visit https://www.researchandmarkets.com/r/jf06ez

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900